...Fitch expects Allergan will look for more strategic transactions, of varying sizes, over the rating horizon. Though aggressive at times, Fitch views Allergan's M&A activity as sound and supportive of an improving business outlook....
Navigator
Enter the keyword(s) you would like to search for within this report:
Fitch Affirms Allergan at 'BBB-'; Outlook Revised to Stable – 2016/04/07 – US$ 149.00
Fitch: New Treasury Rules Sink Pfizer-Allergan Deal – 2016/04/07 – US$ 149.00
Fitch Wire+: Global Pharma M&A Risks – 2015/04/02 – US$ 999.00
Fitch Affirms 30 U.S. Healthcare, Tobacco and Commodity Processor Companies' Ratings – 2015/04/24 – US$ 300.00
Fitch Wire+: Generic Pharma Ratings Face Pressure From M&A Surge – 2015/08/13 – US$ 999.00
Fitch Affirms 30 U.S. Healthcare, Tobacco and Commodity Processor Companies' Ratings – 2015/04/24 – US$ 149.00
Fitch: Allergan's Acquisition of Kythera Within Expectations; No Rating Actions – 2015/06/17 – US$ 149.00
Fitch Affirms Allergan's 'BBB-' Ratings Following Generic Business Sale to Teva – 2015/07/28 – US$ 149.00
Fitch: Generic Pharma Ratings Face Pressure From M&A Surge – 2015/08/13 – US$ 149.00
Fitch Places Allergan's Ratings on Positive Watch Following Pfizer Merger Announcement – 2015/11/23 – US$ 149.00
Fitch Research—Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.
Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.
Search all our Credit Research from one place.